Updates on Anteris Technologies' Special Meeting for Stockholders
Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) has postponed its upcoming Special Meeting of Stockholders. Originally set for a recent Thursday evening, the meeting is now rescheduled to take place online about a week later. This decision comes from a desire to enhance participation and engagement among stockholders, allowing ample time for votes to be cast. With an ongoing commitment to pioneering solutions for structural heart diseases, Anteris values the involvement of its stockholders in pivotal decisions.
Reasons Behind the Postponement
The postponement aims to provide stockholders with more time to review materials and make informed decisions regarding proposals outlined in the official Proxy Statement. The board of directors at Anteris encourages all stockholders to engage in this essential process by voting in favor of the proposals designed to support the company’s strategic goals.
Voting Instructions for Stockholders
For stockholders who have already cast their votes on Common Stock or have given instructions for their CDIs, rest assured that your votes will be respected without any further action needed on your part. For those who have not yet exercised their voting ability, Anteris has detailed instructions available in the Proxy Statement, facilitating easy participation via online or phone methods. Timely submission is crucial to ensure that all votes are counted, promoting a seamless voting experience.
New Date and Meeting Format
The Special Meeting is now set to be held virtually via live webcast. This format choice not only enhances accessibility for stockholders from varied locations but also maintains a focus on transparency and efficient communication regarding the company’s vital activities and future directions. The meeting will occur at the new date and time, aiming to accommodate as many stockholders as possible.
Proxy Voting Details
In order to facilitate a smooth voting process, Anteris emphasizes the importance of timely proxy submissions. To ensure all proxies are properly counted, submissions made through the Internet or by phone must be received by a specific time ahead of the meeting date. For stockholders who have CDIs, instructions are provided to facilitate voting and ensure inclusion in the meeting’s discussions.
Key Information for Stockholders
Anteris has filed a definitive Proxy Statement, which outlines essential information that stockholders should review. The content within this notice is designed to keep stockholders updated on the specifics of the meeting and guidelines for participation. It is beneficial for stockholders to engage with this document fully as it contains important insights into the company’s proposals.
About Anteris Technologies
Anteris Technologies Global Corp. is a leader in the realm of structural heart solutions. Their flagship product, the DurAVR Transcatheter Heart Valve, represents a leap forward in cardiac surgery. Collaboratively developed with top experts in the field, this innovative valve addresses life-threatening conditions caused by aortic stenosis, thereby restoring normal heart function.
The DurAVR valve stands out as it is the first biomimetic valve designed to mirror the function of a healthy aortic valve. Utilizing Anteris’ patented ADAPT tissue technology, the valve offers durability and effectiveness that aims to replicate the natural flow of blood and enhance patient outcomes for those suffering from significant heart conditions.
Frequently Asked Questions
Why did Anteris Technologies postpone the Special Meeting?
The meeting was postponed to give stockholders more time to participate and make informed voting decisions.
What is the new date for the Special Meeting?
The rescheduled Special Meeting is set to occur virtually on a Thursday evening, about a week later than initially planned.
How can stockholders vote for the proposals?
Stockholders can cast their votes online or through the designated Proxy Statement instructions, ensuring they are submitted on time for counting.
What is the significance of the DurAVR valve?
The DurAVR Transcatheter Heart Valve is designed to treat aortic stenosis, offering innovative solutions for restoring heart function with a biomimetic design.
How does Anteris Technologies ensure stockholder engagement?
Anteris encourages stockholders to read the Proxy Statement carefully, interact with the voting process, and engage actively in discussions about proposals affecting the company's future.
